Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists build heart cells in a dish to unravel genetic heart disease

NCT ID NCT02413450

Knowledge-focused Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study collects blood or skin samples from 100 adults with inherited heart rhythm disorders (like Long QT Syndrome or Brugada Syndrome) and healthy volunteers. Researchers will turn these samples into stem cells and then into heart cells to study how these diseases work and test potential treatments in the lab. The goal is to better understand these conditions, not to directly treat participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could lead to better understanding of inherited heart diseases and help test new treatments in the lab.
What could go wrong
This is an early-stage research study, not a treatment trial. It may not directly lead to new therapies, and lab models may not fully replicate human disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Aug 2013

Expected to finish

Aug 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants who have a mutation causing ARVD/C or LQTS or a first degree family member with such a gene mutation. Participants, including patients with ARVD/C or LQTS and family members, who have previously been genotyped for clinically indicated reasons will be approached to join the study.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients and family members 18 years of age or older with inherited cardiac arrhythmias including LQTS, Brugada Syndrome (BrS), cathecholaminergic polymorphic ventricular tachycardia (CPVT) or early repolarization syndrome (ERS) are eligible for enrollment. * All enrolled patients will have undergone clinically indicated genetic testing. Exclusion Criteria: * Age \<18 years * \>85 years * pregnant women * life-limiting co-morbidities * immunocompromise

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arrhythmogenic cardiomyopathy (ac, arvd/C) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

arrhythmogenic right ventricular cardiomyopathy Brugada syndrome cardiac rhythm disease cardiogenetic rhythm disorder catecholaminergic polymorphic ventricular tachycardia Channelopathies dilated cardiomyopathy Duchenne muscular dystrophy early repolarization associated with ventricular fibrillation hypertrophic cardiomyopathy long QT syndrome muscular dystrophy myotonic dystrophy Polymorphic Catecholaminergic Ventricular Tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arrhythmogenic cardiomyopathy (ac, arvd/C) Brugada syndrome (BRS) Catecholaminergic polymorphic ventricular tachycardia (CPVT) Dilated cardiomyopathy (DCM) Early repolarization syndrome (ERS) Hypertrophic cardiomyopathy (HCM) Inherited cardiac arrythmias Long QT syndrome (LQTS) Muscular dystrophies (Duchenne, Becker, myotonic dystrophy) Normal control subjects

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Johns Hopkins Medical Institute

    Baltimore, Maryland, 21287-9106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.